9 September 2015 - The agenda for the 16 September 2015 TC meeting is now available. The Commission will consider the following technologies:

• Certinib (Zykadia) - new medicine
• Cetuximab (Erbitux) - new indication
• Clopidogrel hydrogen sulphate with aspirin (DuoPlaven) - review of ASMR
• Dapaglifliozin propanediol monohydrate (Forxiga) - review of SMR
• Dapagliflozin propanediol monohydrate with metformin hydrochloride (Xigduo) - new combination product
• Regorafenib monohydrate (Stivarga) - new indication
• Hexaminolevulinate hydrochloride (Hexvix) - review of SMR & ASMR
• Safinamide (Zadago) - new medicine

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-09/odj_ct_16092015_internet.pdf [French]